Parietal cells are responsible for gastric acid secretion, which aids in the digestion of food,
absorption of minerals, and control of harmful bacteria. However, a fine balance of activators …

Increasing resistance to antibiotics worldwide has adverse effects on the effectiveness of
standard therapies to eradicate Helicobacter pylori infection. We reviewed guidelines …

Background Potassium‐competitive acid blockers (P‐CAB) are recommended for the
treatment of Helicobacter pylori infections, but dual therapy of P‐CAB with amoxicillin has …

This review summarizes important studies regarding Helicobacter pylori therapy published
from April 2019 to April 2020. The main themes that emerge involve studies assessing …

Conventional proton pump inhibitors (PPIs) are used as a first-line therapy to treat acid-
related diseases worldwide. However, they have a number of limitations including slow …

The main challenge in the field of Helicobacter pylori (H. pylori) infection is antibiotic
resistance, which influences the efficacy of eradication regimens. Bismuth-containing …

Aims Nocturnal acid breakthrough has been considered an unmet need of proton‐pump
inhibitors. Tegoprazan, a novel potassium‐competitive acid blocker, is expected to show …

Background Vonoprazan‐amoxicillin (VA) dual therapy has been shown to achieve
acceptable cure rates for treatment of Helicobacter pylori (H. pylori) in Japan. Its …

Abstract Background and Aim Potassium‐competitive acid blocker (PCAB) is a recent
alternative to proton pump inhibitor (PPI) for potent acid suppression. The current systematic …

Background Recent clinical trials have evaluated the efficacy of vonoprazan‐amoxicillin
(VA) dual therapy as the first‐line treatment for Helicobacter pylori infection in different …